I/LA25

This document addresses the steps required to provide reliable screening and reporting using examples of serum markers currently in common use (AFP, hCG, uE3, inhibin A, PAPP-A). Emphasized is first-trimester screening, in which serum markers used are PAPP-A and hCG , and the main ultrasound marker is nuchal translucency. Outcome evaluation, information management, and calculation of risk are also emphasized. 

This reaffirmed document has been reviewed and confirmed as suitable to remain published without revision to content, as of September 2018. The document’s next scheduled review is generally five years after the reaffirmation date.

This document is available in electronic format only.

More Details